-
Mashup Score: 1In Search of Representative Translational Cancer Model Systems - 17 day(s) ago
Racial disparities in cancer outcomes are well documented across tumor types. For patients with breast cancer, Black women are more likely to present with more aggressive molecular features and more likely to die from disease, even after accounting for those features. Recent efforts have been aimed at developing translational model systems for precision medicine strategies, and a major focus has been on patient-derived organoids. Organoids allow for robust in vitro experimental platforms, including drug and CRISPR screens while maintaining more complex cancer and tumor microenvironment subpopulations than cell lines. For results that are broadly translationally relevant, it is important that cancer models are derived from the spectrum of human disease and humans with disease. In this issue of Cancer Research, Madorsky Rowdo and colleagues derive breast cancer organoids from patients with African ancestry and use CRISPR-Cas9 screens to identify novel therapeutic vulnerabilities. These f
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Generation of a breast cancer patient-derived tumor organoid biobank focused on underrepresented populations enabled kinome-focused CRISPR screening that identified essential kinases and potential targets for combination therapy with EGFR or MEK inhibitors.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
New in Translational Cancer Biology: Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition https://t.co/8ensBZSuXH https://t.co/IiPkJ750gw
-
-
Mashup Score: 0
Abstract. Cancer genomics consortia have identified somatic drivers of breast cancer subtypes. However, these studies have predominantly included older, non-Black women, and the related socioeconomic status (SES) data is limited. Increased representation and depth of social data are crucial for understanding how health inequity is intertwined with somatic landscapes. Here, we conducted targeted sequencing on primary tumors from the Carolina Breast Cancer Study (N = 357; 52% Black, 47% <50) and compared the results to The Cancer Genome Atlas (N = 948; 18% Black, 27% <50). Race (Black vs. non-Black), age, and SES were evaluated in association with mutations, copy number alterations, and aneuploidy using generalized linear models. Pathway dysfunction was also assessed by aggregating mutation and copy number alterations. Adjusting for age, Black participants (N =350) were significantly more likely to have TP53 and FAT1 mutations and less likely to have PIK3CA, CDH1, DDR2, and GATA3 mutatio
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Online now in our Convergence Science section "Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors" https://t.co/K2uUwLiWQV By @MelissaTroester et al. https://t.co/Cvykf0ewGl
-
-
Mashup Score: 2
Call for Papers | Cancer Research | American Association for Cancer Research .aacrcontent ul {list-style-image: url(‘/ImageLibrary/CR/icons/cr_bullet.png’);} .banner{ display: block; width: 100% margin: -20px; } .banner-sm{ display: none; } h3 { margin-top: 22px; } .aacrbutton { background-color: #50b848; border: none; color: white; padding: 8px 32px; text-align: center; text-decoration: none; display: inline-block; font-size: 1.3em; margin: 16px auto 16px auto; border: 2px solid #e7e7e7; border-radius:…
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Submit your Research Article or Resource Report to Cancer Research’s special series—Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI—launching in July 2025. Learn more: https://t.co/GasUi4HcYJ https://t.co/roI0cVU7G7
-
-
Mashup Score: 1Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling - 19 day(s) ago
CD36 in tumor-associated macrophages mediates immunosuppression and can be targeted as a therapeutic avenue for stimulating interferon production and increasing the efficacy of immunotherapy.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
New in Cancer Immunology: Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling https://t.co/GInARsJgTa https://t.co/P4XyXRsnE9
-
-
Mashup Score: 0Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer - 19 day(s) ago
Elevated IGFBP2 secretion by uterine cancer cells with heterozygous PPP2R1A mutations supports tumor progression and confers a vulnerability to IGFBP2/IGF1R inhibition as a therapeutic approach for this highly aggressive cancer subtype.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
New in Cancer Biology: Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer https://t.co/7iGQtVHjyn https://t.co/gyND9yuNpO
-
-
Mashup Score: 1
Abstract. A recent publication by Bornes and colleagues explored the impact of the estrous cycle on mammary tumor response to neoadjuvant chemotherapy (NAC). Using genetically engineered mouse models, Bornes and colleagues revealed that chemotherapy is less effective when initiated during the diestrus stage compared to during the estrus stage. A number of changes during diestrous were identified that may reduce chemosensitivity of mammary tumors: an increased mesenchymal state of breast cancer cells during diestrous, decreased blood vessel diameters, and higher numbers of macrophages in the tumor microenvironment. Macrophage depletion was sufficient to mitigate this resistance. To translate these findings to humans, retrospective analyses of premenopausal breast cancer patients were conducted. Serum progesterone levels served to determine the menstrual cycle phases, which revealed that treatment efficacy is reduced in women receiving NAC during the luteal (progesterone-high) phase comp
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
In the Spotlight- Breaking the Rhythm: Harnessing the Menstrual Cycle for Better Chemotherapy Pranay Dey and Cathrin Brisken discuss a recent Nature paper by @vanRheenen_Lab @ColindaScheele et al. https://t.co/1h7x46Kafo https://t.co/TfHCGyfO1z
-
-
Mashup Score: 1Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma - 22 day(s) ago
The development of c-MYC–driven genetically engineered neuroblastoma and somatostatinoma mouse models provides useful tools for understanding the tumor cell origin and investigating treatment strategies.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
New in Cancer Biology: Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma https://t.co/ArtuyrBb5y https://t.co/ffNkQCSt9I
-
-
Mashup Score: 21
Abstract. Fungal dysbiosis is increasingly recognized as a key factor in cancer, influencing tumor initiation, progression, and treatment outcomes. This review explores the role of fungi in carcinogenesis, with a focus on mechanisms such as immunomodulation, inflammation induction, tumor microenvironment remodeling, and interkingdom interactions. Fungal metabolites are involved in oncogenesis, and antifungals can interact with anticancer drugs, including eliciting potential adverse effects and influencing immune responses. Furthermore, mycobiota profiles have potential as diagnostic and prognostic biomarkers, emphasizing their clinical relevance. The interplay between fungi and cancer therapies can affect drug resistance, therapeutic efficacy, and risk of invasive fungal infections associated with targeted therapies. Finally, emerging strategies for modulating mycobiota in cancer care are promising approaches to improve patient outcomes.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Fungal Influences on Cancer Initiation, Progression, and Response to Treatment https://t.co/3DCIJk5wWY https://t.co/Jx5TuHMRAS
-
-
Mashup Score: 21
Abstract. Fungal dysbiosis is increasingly recognized as a key factor in cancer, influencing tumor initiation, progression, and treatment outcomes. This review explores the role of fungi in carcinogenesis, with a focus on mechanisms such as immunomodulation, inflammation induction, tumor microenvironment remodeling, and interkingdom interactions. Fungal metabolites are involved in oncogenesis, and antifungals can interact with anticancer drugs, including eliciting potential adverse effects and influencing immune responses. Furthermore, mycobiota profiles have potential as diagnostic and prognostic biomarkers, emphasizing their clinical relevance. The interplay between fungi and cancer therapies can affect drug resistance, therapeutic efficacy, and risk of invasive fungal infections associated with targeted therapies. Finally, emerging strategies for modulating mycobiota in cancer care are promising approaches to improve patient outcomes.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Fungal Influences on Cancer Initiation, Progression, and Response to Treatment https://t.co/3DCIJk5wWY https://t.co/Jx5TuHMRAS
-
Read the commentary: In Search of Representative Translational Cancer Model Systems https://t.co/TO5O701dVz https://t.co/wqoSujm7CX